TP A4: The pathophysiological role of Th17cells in Bullous pemphigoid

We recently demonstrated an important role of IL-17A in the effector phase of epidermolysis bullosa acquisita (EBA, TP 4). Here, we will investigate if blockade of IL-17A is therapeutically active in immunization induced bullous pemphigoid. Subsequently we will perform a proof-of-concept clinical trail in bullous pemphigoid patients using anti-IL17. In these patients we will in detail characterize the effects on antigen-specific T and B cells.